(July 2): AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the US, the Times reported on Tuesday, citing multiple sources. Any such move would be a major blow to the UK stock market, which has seen a string of delistings and missed out on some major initial public offerings in recent months. CEO Pascal Soriot has privately expressed a preference to shift AstraZeneca's listing on multiple occasions and has also discussed relocating the company's domicile, the Times said. AstraZeneca, which has a market value of about £156 billion (RM901.13 billion), declined to comment. Its US plans include a US$3.5 billion investment in domestic manufacturing by the end of 2026.

Source: The Times July 02, 2025 05:07 UTC